OBJECTIVE: Anakinra has been increasingly used in off-label indications as well as dosing and mode of administration in a variety of inflammatory conditions. We aimed to review our clinical practice and compare treatment outcomes with published data. METHODS: Clinical data from electronic records were retrospectively reviewed for patients treated with anakinra over the past 6 years for autoinflammatory diseases (AID). RESULTS: From 47 eligible patients (27 female patients), 32 were children. Macrophage activation syndrome (MAS) was the indication for anakinra therapy in 42.6% of patients. Systemic juvenile idiopathic arthritis (SJIA) was the most common underlying diagnosis (19/47) followed by the spectrum of AID. Off-label use was noted in 38.3% patients. Recommended dose was exceeded in 21 children (mean induction dose 5.1, highest dose 29.4 mg/kg/day) and two adults; five patients were treated intravenously. The mean treatment duration for SJIA was 1.4 years, that for AID was 2.2 years, and that for patients with higher anakinra dose was 9.7 (19.3) months. The mean follow-up duration was 2.7 (1.7) years. Treatment was effective in the majority of SJIA and cryopyrinopathy patients as well as those with MAS. Anakinra was well-tolerated without any major adverse effects even in patients with long-term administration of higher than recommended doses including two infants treated with a dose of over 20 mg/kg/day. CONCLUSION: Our results support early use of anakinra in the individually tailored dosing. In patients with hyperinflammation, anakinra may be lifesaving and may even allow for corticosteroid avoidance. Further studies are needed in order to set up generally accepted response parameters and define condition-specific optimal dosing regimen.

Centre for Paediatric Rheumatology and Autoinflammatory Diseases Department of Paediatrics and Inherited Metabolic Disorders 1st Faculty of Medicine Charles University and General University Hospital Prague Czechia

Department of Nephrology 1st Faculty of Medicine Charles University and General University Hospital Prague Czechia

See more in PubMed

Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. (2012) 11:633–52. 10.1038/nrd3800 PubMed DOI PMC

Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med. (2014) 65:223–44. 10.1146/annurev-med-061512-150641 PubMed DOI PMC

Federici S, Martini A, Gattorno M. The Central Role of Anti-IL-1 Blockade in the treatment of monogenic and multi-factorial autoinflammatory diseases. Front Immunol. (2013) 4:351. 10.3389/fimmu.2013.00351 PubMed DOI PMC

ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. . Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. (2015) 74:1636–44. 10.1136/annrheumdis-2015-207546 PubMed DOI

Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. . Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. (2011) 63:545–55. 10.1002/art.30128 PubMed DOI

Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, et al. . 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. (2013) 65:2499–512. 10.1002/art.38092 PubMed DOI PMC

European Medicines Agency,. Kineret. (2021). Available online at: https://www.ema.europa.eu/en/medicines/human/EPAR/kineret (accessed December 22, 2021).

Maniscalco V, Abu-Rumeileh S, Mastrolia MV, Marrani E, Maccora I, Pagnini I, et al. . The off-label use of anakinra in pediatric systemic autoinflammatory diseases. Ther Adv Musculoskelet Dis. (2020) 12:1759720X20959575. 10.1177/1759720X20959575 PubMed DOI PMC

Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, et al. . Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. (2015) 10:19. 10.1186/s13023-015-0228-7 PubMed DOI PMC

Tombetti E, Mule A, Tamanini S, Matteucci L, Negro E, Brucato A, et al. . Novel Pharmacotherapies for Recurrent Pericarditis: current options in 2020. Curr Cardiol Rep. (2020) 22:59. 10.1007/s11886-020-01308-y PubMed DOI PMC

Gambacorta A, Buonsenso D, De Rosa G, Lazzareschi I, Gatto A, Brancato F, et al. . Resolution of giant coronary aneurisms in a child with refractory Kawasaki disease treated with anakinra. Front Pediatr. (2020) 8:195. 10.3389/fped.2020.00195 PubMed DOI PMC

Deshayes S, Georgin-Lavialle S, Hot A, Durel CA, Hachulla E, Rouanes N, et al. . Efficacy of Continuous interleukin 1 blockade in mevalonate kinase deficiency: a multicenter retrospective study in 13 adult patients and literature review. J Rheumatol. (2018) 45:425–9. 10.3899/jrheum.170684 PubMed DOI

Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, et al. . A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol. (2016) 7:380. 10.3389/fphar.2016.00380 PubMed DOI PMC

Papadopoulou C, Al Obaidi M, Moraitis E, Compeyrot-Lacassagne S, Eleftheriou D, Brogan P. Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist. Rheumatology (Oxford). (2021) 60:911–7. 10.1093/rheumatology/keaa652 PubMed DOI PMC

Pasin L, Cavalli G, Navalesi P, Sella N, Landoni G, Yavorovskiy AG, et al. . Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. Eur J Intern Med. (2021) 86:34–40. 10.1016/j.ejim.2021.01.016 PubMed DOI PMC

Monteagudo LA, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol. (2020) 2:276–82. 10.1002/acr2.11135 PubMed DOI PMC

Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. (2020) 2:e358–e67. 10.1016/S2665-9913(20)30096-5 PubMed DOI PMC

Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. . Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. (2016) 44:275–81. 10.1097/CCM.0000000000001402 PubMed DOI PMC

Wampler Muskardin TL. Intravenous anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of coronavirus disease 2019. ACR Open Rheumatol. (2020) 2:283–5. 10.1002/acr2.11140 PubMed DOI PMC

Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. . COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. (2020) 20:e276–e88. 10.1016/S1473-3099(20)30651-4 PubMed DOI PMC

Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J, Waters G, et al. . Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health. (2020) 4:669–77. 10.1016/S2352-4642(20)30215-7 PubMed DOI PMC

Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. . American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol. (2021) 73:e13–e29. 10.1002/art.41616 PubMed DOI PMC

Ajeganova S, De Becker A, Schots R. Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance. Ther Adv Musculoskelet Dis. (2020) 12:1759720X20974858. 10.1177/1759720X20974858 PubMed DOI PMC

Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al. . Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. (2010) 62:258–67. 10.1002/art.25057 PubMed DOI

Harrison SR, McGonagle D, Nizam S, Jarrett S, van der Hilst J, McDermott MF, et al. . Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight. (2016) 1:e86336. 10.1172/jci.insight.86336 PubMed DOI PMC

Kavirayani A, Charlesworth JEG, Segal S, Kelly D, Wilson S, Qureshi A, et al. . The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLH. Lancet Rheumatol. (2020) 2:e736–e8. 10.1016/S2665-9913(20)30361-1 PubMed DOI PMC

Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. . International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. (2004) 31:390–2. PubMed

Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al. . 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. (2016) 68:566–76. 10.1002/art.39332 PubMed DOI

Papa R, Penco F, Volpi S, Sutera D, Caorsi R, Gattorno M. Syndrome of undifferentiated recurrent fever (SURF): an emerging group of autoinflammatory recurrent fevers. J Clin Med. (2021) 10:1963. 10.3390/jcm10091963 PubMed DOI PMC

Fingerhutova S, Franova J, Hlavackova E, Jancova E, Prochazkova L, Berankova K, et al. . Muckle-wells syndrome across four generations in one czech family: natural course of the disease. Front Immunol. (2019) 10:802. 10.3389/fimmu.2019.00802 PubMed DOI PMC

Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C, et al. . Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. (2013) 72:678–85. 10.1136/annrheumdis-2011-201268 PubMed DOI

Garg S, Wynne K, Omoyinmi E, Eleftheriou D, Brogan P. Efficacy and safety of anakinra for undifferentiated autoinflammatory diseases in children: a retrospective case review. Rheumatol Adv Pract. (2019) 3:rkz004. 10.1093/rap/rkz004 PubMed DOI PMC

Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, et al. . Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. (2020) 72:326–34. 10.1002/art.41103 PubMed DOI

Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S. Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J. (2021) 19:98. 10.1186/s12969-021-00585-3 PubMed DOI PMC

Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. . Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. (2020) 2:e325–e31. 10.1016/S2665-9913(20)30127-2 PubMed DOI PMC

Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. . Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. (2020) 383:334–46. 10.1056/NEJMoa2021680 PubMed DOI PMC

Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. . Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. (1997) 25:1115–24. 10.1097/00003246-199707000-00010 PubMed DOI

Urien S, Bardin C, Bader-Meunier B, Mouy R, Compeyrot-Lacassagne S, Foissac F, et al. . Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC Pharmacol Toxicol. (2013) 14:40. 10.1186/2050-6511-14-40 PubMed DOI PMC

Shafferman A, Birmingham JD, Cron RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr Rheumatol Online J. (2014) 12:26. 10.1186/1546-0096-12-26 PubMed DOI PMC

Kenney-Jung DL, Vezzani A, Kahoud RJ, LaFrance-Corey RG, Ho ML, Muskardin TW, et al. . Febrile infection-related epilepsy syndrome treated with anakinra. Ann Neurol. (2016) 80:939–45. 10.1002/ana.24806 PubMed DOI PMC

Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. . Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. (2014) 66:1034–43. 10.1002/art.38296 PubMed DOI

Ter Haar N, Van Dijkhuizen EHP, Swart JF, Royen-Kerkhof AV, El Idrissi A, Leek AP, et al. . Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol. (2019) 71:1163–73. 10.1002/art.40865 PubMed DOI PMC

Pardeo M, Rossi MN, Pires Marafon D, Sacco E, Bracaglia C, Passarelli C, et al. . Early treatment and IL1RN single-nucleotide polymorphisms affect response to anakinra in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. (2021) 73:1053–61. 10.1002/art.41612 PubMed DOI

Sonmez HE, Demir S, Bilginer Y, Ozen S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol. (2018) 37:3329–35. 10.1007/s10067-018-4095-1 PubMed DOI

Bami S, Vagrecha A, Soberman D, Badawi M, Cannone D, Lipton JM, et al. . The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. (2020) 67:e28581. 10.1002/pbc.28581 PubMed DOI

Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, et al. . Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. (2019) 78:1722–31. 10.1136/annrheumdis-2019-216040 PubMed DOI PMC